Skip to main content
OpenTrials

Clinical trial condition

Chronic Lymphocytic Leukemia

Explore clinical trials studying Chronic Lymphocytic Leukemia. Study availability and eligibility vary by location and protocol.

528 public trials 91 recruiting studies
Refine in advanced search Browse all conditions

Chronic Lymphocytic Leukemia trial results

Active, Not Recruiting

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

NCT05624554

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • Highlands Oncology Group ( Site 5205) Springdale, Arkansas, United States
  • Clermont Oncology Center ( Site 5224) Clermont, Florida, United States
  • Hattiesburg Clinic Hematology/Oncology ( Site 5216) Hattiesburg, Mississippi, United States
  • Medical Oncology Associates, PS ( Site 5206) Spokane, Washington, United States
View all 97 locations
View Trial Details
Active, Not Recruiting

PICAROS - Acalabrutinib RWE on 1L CLL in Spain

NCT05999877

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Research Site Almería, Andalusia, Spain
  • Research Site Córdoba, Andalusia, Spain
  • Research Site Granada, Andalusia, Spain
  • Research Site Jaén, Andalusia, Spain
View all 47 locations
View Trial Details
Active, Not Recruiting

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

NCT03336333

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • Augusta University Augusta, Georgia, United States
  • Northwestern University Chicago, Illinois, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Research Medical Center Kansas City, Missouri, United States
View all 158 locations
View Trial Details
Active, Not Recruiting

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period

NCT06524375

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Highlands Oncology Group Springdale, Arkansas, United States
  • Rocky Mountain Cancer Centers (Aurora) - USOR Aurora, Colorado, United States
  • Cancer Specialists of North Florida Jacksonville, Florida, United States
  • Fort Wayne Medical Oncology and Hematology, Inc Fort Wayne, Indiana, United States
View all 20 locations
View Trial Details

Related conditions